-
Mashup Score: 1The OncoAlert Newsletter is NOW OUT Click to Register - 17 hour(s) ago
The OncoAlert Newsletter is now out for June 23-29, 2023
Source: www.OncoAlert360.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1The OncoAlert Newsletter is NOW OUT Click to Register - 1 day(s) ago
The OncoAlert Newsletter is now out for June 23-29, 2023
Source: www.OncoAlert360.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1The OncoAlert Newsletter is NOW OUT Click to Register - 2 day(s) ago
The OncoAlert Newsletter is now out for June 23-29, 2023
Source: www.OncoAlert360.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7
Summary. Combination immune-checkpoint inhibition with chemotherapy is a clinical standard, yet concurrent administration may limit the full benefit of immunotherapy by blunting the proliferation and differentiation of CD8 T cells. Identifying patients in whom sequential chemo-immunotherapy or immunotherapy alone is feasible should be a priority to optimize long-term outcomes.See related article by Mariniello et al., p. 1833
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 73Hallmarks of cancer stemness - 6 day(s) ago
Cancer stemness, regarded as a crucial factor in tumor development, has been recognized to involve a plastic cellular state influenced by dynamic interactions between cancer stem cells (CSCs) and their niche. Herein, we provide a summary of the defining and emerging hallmarks of CSCs and/or cancer stemness.
Source: www.cell.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4
AbstractPurpose:. Immune checkpoint inhibitors (ICI) have been a potential treatment option for patients with cervical cancer in several clinical studies. We investigated the safety and efficacy of cadonilimab, a bispecific antibody targeting PD-1 and CTLA-4, plus standard therapy for the first-line treatment of R/M CC (recurrent and/or metastatic cervical cancer).Patients and Methods:. Eligible patients were assigned to 3 cohorts: cohort A-15 (cadonilimab 15 mg/kg every 3 weeks (Q3W) plus chemotherapy), cohort A-10 (cadonilimb 10 mg/kg Q3W plus chemotherapy), and cohort B-10 (cadonilimab 10 mg/kg Q3W plus chemotherapy and bevacizumab). They received the corresponding treatments until disease progression, unacceptable toxicity, withdrawal of consent, or investigator decision. The primary objective was safety; the secondary endpoints included objective overall response (ORR), duration of response, disease control rate, progression-free survival, and overall survival. This study is regis
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 20The OncoAlert ASCO 5k Registration - 11 day(s) ago
Registration for the OncoAlert ASCO 5k to be held on June 1st, 2024 at 7am local time and will start at the Hyatt Regency McCormick place, up to Chicago Harbour and ending at the starting place
Source: oncoalert.m-pages.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 20The OncoAlert ASCO 5k Registration - 11 day(s) ago
Registration for the OncoAlert ASCO 5k to be held on June 1st, 2024 at 7am local time and will start at the Hyatt Regency McCormick place, up to Chicago Harbour and ending at the starting place
Source: oncoalert.m-pages.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1The OncoAlert Newsletter is NOW OUT Click to Register - 14 day(s) ago
The OncoAlert Newsletter is now out for June 23-29, 2023
Source: www.OncoAlert360.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1The OncoAlert Newsletter is NOW OUT Click to Register - 14 day(s) ago
The OncoAlert Newsletter is now out for June 23-29, 2023
Source: www.OncoAlert360.comCategories: General Medicine News, Onc News and JournalsTweet
RT @BenWestphalen: Out today ๐ฅ The new @OncoAlert ๐จ #newsletter - if you donโt want to miss out: register at https://t.co/AxMKHsMAQC ๐